Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221708 · ClinicalTrials.gov registry record · Phase 2
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07221708 is a Phase 2 study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 200 participants.
The verdict
NCT07221708, a Phase 2 study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics. Participants in this study will be placed randomly into two groups. The oral vancomycin treatment group will receive oral vancomycin two times per day simultaneously with an antibiotic plus two additional days. The no oral vancomycin control group will receive the current standard of care, which is an antibiotic and no oral vancomycin. Participation in this study will last approximately 3 months.
Interventions
- DRUG Vancomycin (POC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221708
The ClinicalTrials.gov registry entry for NCT07221708 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vancomycin (POC) is the first listed.
NCT07221708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221708 about?
NCT07221708 is a clinical study titled "Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin". The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics. Participants in this study will be placed randomly into two groups. The oral vancomycin treatment group will rece...
What is the current status of trial NCT07221708?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-03-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07221708?
The interventions under investigation include: Vancomycin (POC) (DRUG).
Who is sponsoring clinical trial NCT07221708?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.